statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InflaRx N.V. Announces 2024 AGM Details

Inflarx N.V. (IFRX) has released an update. InflaRx N.V. has announced its annual general meeting (AGM) to be held in Amsterdam on April 25, 2024...

InflaRx (NASDAQ:IFRX) Stock Rating Reaffirmed by HC Wainwright

InflaRx (NASDAQ:IFRX  Get Free Report)s stock had its buy rating restated by HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They...

Q4 2023 InflaRx NV Earnings Call Transcript

InflaRx reports FY results

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR...

Earnings Preview: InflaRx

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

Head to Head Survey: InflaRx (NASDAQ:IFRX) and Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO  Get Free Report) and InflaRx (NASDAQ:IFRX  Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the...

InflaRx Appoints Jan Medina as Head of Investor Relations

JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

InflaRx (NASDAQ:IFRX) Short Interest Update

InflaRx (NASDAQ:IFRX  Get Free Report) was the recipient of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 307,000 shares, a...

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Volume	87,651.00
52-Wk High	$4.30
52-Wk Low	$1.14

IFRX InflaRx N.V.

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community